Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT05316155
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05316155 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Focused
We haven't built an HCP commentary report on NCT05316155 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05316155 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Erdafitinib Intravesical Delivery System
- Arms
- Part 1: Dose Escalation · Experimental
- Part 2: Dose Expansion · Experimental
- Part 3: RP2D Dose Expansion · Experimental
- Part 4: Phase 2 Expansion · Experimental
- Enrollment
- 235
- Primary outcomes
- Parts 1 to 3: Number of Participants with Adverse Events (AEs)
- Parts 1 to 3: Number of Participants with AEs by Severity
- Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
- Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Apr 11, 2022
- Primary completion
- Mar 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05316155 · updated Sep 25, 2026